2. PI3K/Akt/mTOR Apoptosis NF-κB Immunology/Inflammation Metabolic Enzyme/Protease MAPK/ERK Pathway Stem Cell/Wnt Neuronal Signaling Membrane Transporter/Ion Channel Anti-infection
  3. Akt Apoptosis NF-κB Reactive Oxygen Species (ROS) p38 MAPK ERK Interleukin Related TNF Receptor NO Synthase nAChR Bacterial
  4. Crebanine

Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC50 of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the AKT/FoxO3a, NF-κB and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation. Crebanine inhibits voltage-dependent Na+ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease.

For research use only. We do not sell to patients.

Crebanine

Crebanine Chemical Structure

CAS No. : 25127-29-1

Size Price Stock Quantity
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO
ready for reconstitution
 In-stock
Solution
10 mM * 1 mL in DMSO In-stock
Solid
1 mg In-stock
5 mg In-stock
10 mg In-stock
20 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 3 publication(s) in Google Scholar

Crebanine Related Antibodies

Top Publications Citing Use of Products

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All NF-κB Isoform Specific Products:

View All Isoforms
NF-κB NF-κB1/p50 RelA/p65 RelB c-Rel

View All p38 MAPK Isoform Specific Products:

View All Isoforms
p38 MAPK p38α p38β MAPK13 p38δ p38γ

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Interleukin Related Isoform Specific Products:

View All Isoforms
IL-1 IL-2 IL-3 IL-4 IL-5 IL-6 IL-8 IL-10 IL-12 IL-13 IL-15 IL-17 IL-23 IL-7 IL-33 IL-22

View All TNF Receptor Isoform Specific Products:

View All Isoforms
TNFRSF1A/CD120a TNFRSF3/CD18 TNFRSF4 TNFRSF5/CD40 TNFRSF6/Fas/CD95 TNFRSF7/CD27 TNFRSF8/CD30 TNFRSF9/4-1BB/CD137 TNFRSF12A/TWEAK TNFRSF16/NGF Receptor/CD271 TNFRSF18/GITR/CD357

View All NO Synthase Isoform Specific Products:

View All Isoforms
nNOS iNOS eNOS

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Crebanine is an isoquinoline-like alkaloid that can be derived from Stephania. Crebanine is an antagonist of the α7-nAChR with an IC50 of 19.1 μM. Crebanine suppresses the proliferation, migration, and invasion of cancer cells, triggers reactive oxygen species (ROS) burst, and promotes apoptosis. Crebanine inhibits the AKT/FoxO3a, NF-κB and MAPK signaling pathways. Crebanine attenuates NOX2 hyperactivation, exhibits antioxidant properties by reducing reactive oxygen species and peroxidation. Crebanine inhibits voltage-dependent Na+ current in guinea-pig ventricular myocytes. Crebanine has high inhibitory activity against gram-positive animal pathogenic bacteria. Crebanine ameliorates ischemia-reperfusion brain damage in middle cerebral artery occlusion and reperfusion (MCAO/R) rats. Crebanine significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice. Crebanine can be used for the study of hepatocellular carcinoma (HCC), cerebral ischemia and Alzheimer's disease[1][2][3][4][5][6].

In Vitro

Crebanine (0-280 μM, 24-72 h) suppresses cell growth, reduces colony formation ability and inhibits migration and invasion of HepG2 cells[1].
Crebanine (35-175 μM, 24 h) reduces mitochondrial membrane potential (MMP) and induces apoptosis rate in HepG2 cells[1].
Crebanine (35-175 μM, 24 h) increases intracellular ROS levels, enhances MDA production, and decreases SOD and GSH-PX activities in HepG2 cells, an effect that can be reversed by Acetylcysteine (NAC) (HY-B0215) pretreatment[1].
Crebanine (35-175 μM, 24 h) down-regulates p-AKT and p-FoxO3a (Ser253) in HepG2 cells in a dose-dependent manner without affecting total AKT and FoxO3a levels[1].
Crebanine (1-20 μM, pretreated for 2 h, then co-treated with LPS for 24 h) inhibits NOX2 activation in BV-2 cells by reducing NADP⁺/NADPH levels, downregulating gp91phox and p47phox expression, and decreasing p47phox membrane translocation[2].
Crebanine (1-20 μM, pretreated for 2 h, then co-treated with LPS (HY-D1056) for 24 h) reduces intracellular superoxide anion, ROS, and MDA levels, suppresses NO, iNOS, IL-1β, IL-6, and TNF-α expression, and inhibits NF-κB and MAPK signaling pathways[2].
Crebanine (0-30 µg/mL, 48 h) inhibits proliferation of HL-60, U937, K562, HT1080, KB-3-1 and KB-V1 cells in a concentration-dependent manner with IC50 values of 9, 12, 13, 20, 24 and 16 µg/mL respectively, and shows slight toxicity to normal fibroblast cells (72% survival at 30 µg/mL)[3].
Crebanine (0-30 µg/mL, 24 h) induces G0/G1 phase arrest and induces apoptosis in HL-60 and U937 cells[3].
Crebanine (20 µg/mL, 0-24 h) down-regulates the expression of cyclins A, D1, PCNA, Bcl-2 and Bcl-xl and enhances Bax expression in HL-60 cells, while cyclin E expression remains unchanged[3].
Crebanine (0.0368-0.7366 mM) reversibly inhibits voltage-dependent Na⁺ current in guinea-pig ventricular myocytes in a concentration-dependent manner, with an IC50 of 0.283 mM; the effect partially recovers after 5 min washout[4].
Crebanine (10 μM) significantly inhibits the binding of (±)-[³H]-epibatidine to Ls-AChBP, Ac-AChBP and AcY55W-AChBP, with Ki values of 179 nM, 538 nM and >1000 nM respectively[5].
Crebanine (10.3 μM) exhibits antagonistic effects on α7-nAChR, α4β2-nAChR, (α1)2β1δγ-nAChR and 5-HT3A receptor in mammalian cells, with inhibition percentages of 100.7%, 29.0%, 81.7% and 55.3% respectively[5].
Crebanine exhibits high inhibitory activity against gram-positive animal pathogenic bacteria, with an MIC of 0.312 g/L against Micrococcus lysodeikticus, Bacillus megaterium, Bacillus subtilis and Staphylococcus aureus, and an MIC of 0.213 g/L against Bacillus cereus[6].
Crebanine inhibits hyphal growth of these 5 plant pathogenic fungi (EC50: 0.111 g/L for Cercospora kaki; 6.47×10-2 g/L for Gymnosporangium haraeanum; 1.89×10-2 g/L for Pyricularia oryzae; 4.25×10-2 g/L for Rhizoctonia solani; 4.05×10-2 g/L for Colletotrichum graminicola)[6].
Crebanine (0.4 g/L) inhibits spore germination of Thielaviopsis paradoxa (94.96%), Fusarium oxysporum f. sp. niveum (100%), Sphaceloma fawcettii (100%) and Gymnosporangium haraeanum (100%)[6].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Crebanine Related Antibodies

Cell Viability Assay[1]

Cell Line: HepG2 cells
Concentration: 0, 35, 70, 105, 140, 175, 280 µM
Incubation Time: 24, 48, 72 h
Result: Inhibited viability of HepG2 cells in a dose- and time-dependent manner, with IC50 values of 111.77 μM (24 h), 65.07 μM (48 h), and 23.68 μM (72 h).

Cell Invasion Assay[1]

Cell Line: HepG2 cells
Concentration: 35, 105, 175 µM
Incubation Time: 24 h
Result: Inhibited invasion of HepG2 cells in a dose-dependent manner.

Cell Migration Assay [1]

Cell Line: HepG2 cells
Concentration: 35, 105, 175 µM
Incubation Time: 24 h
Result: Inhibited migration of HepG2 cells in a dose-dependent manner.

Apoptosis Analysis[1]

Cell Line: HepG2 cells
Concentration: 35, 105, 175 µM
Incubation Time: 24 h
Result: Increased apoptosis rate (up to 43.5% at highest dose) detected by flow cytometry with Annexin V-FITC/PI staining.

Western Blot Analysis[1]

Cell Line: HepG2 cells
Concentration: 35, 105, 175 µM
Incubation Time: 24 h
Result: Up-regulated Bax, cleaved-PARP, cleaved-caspase-3, and cleaved-caspase-9.
Down-regulated Bcl-2, p-AKT and p-FoxO3a (Ser253).

ELISA Assay[2]

Cell Line: BV2 cells
Concentration: 1, 10, 20 μM
Incubation Time: Pretreated for 2 h, then co-treated with LPS for 24 h
Result: Suppressed IL-1β, IL-6, and TNF-α expression.
In Vivo

Crebanine (250-500 μg/kg, after 2 h MCAO occlusion followed by 24 h reperfusion) ameliorates neurological deficits, reduces brain water content and infarct volume in MCAO/R rats[2].
Crebanine (8.5 mg/kg (25 μmol/kg), i.p., single dose) significantly improves Scopolamine (HY-N0296)-induced cognitive deficits in ICR mice[5].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Adult Sprague-Dawley (SD) rats were used to establish the middle cerebral artery occlusion and reperfusion (MCAO/R) model by a modified monofilament nylon suture embolism method[1]
Dosage: 250-500 μg/kg
Administration: After 2 h MCAO occlusion followed by 24 h reperfusion
Result: Reduced brain water content and infarct volume in MCAO/R rats, with 500 μg/kg exhibiting obvious efficacy.
Up-regulated NeuN⁺ fluorescence density and down-regulated FJB⁺ cell count in the ischemic cortex of MCAO/R rats.
Mitigated synaptic damage induced by MCAO/R operation.
Attenuated NOX2 hyperactivation by reducing NADP⁺ and NADPH levels, suppressing gp91phox and p47phox expressions, and decreasing p47phox membrane translocation in Iba-1⁺ cells of MCAO/R rats.
Reduced the quantity of Iba-1⁺ cells and protein expression in MCAO/R rats.
Exhibited antioxidant properties by down-regulating superoxide anion and intracellular ROS, and reducing lipid and DNA peroxidation in MCAO/R rats.
Exerted anti-inflammatory effects by reducing NO, IL-1β, TNF-α, IL-6, and iNOS expressions in MCAO/R rats.
Inhibited NF-κB and MAPK signaling pathways in MCAO/R rats, as evidenced by reduced NF-κB p65 promoter activity and nucleus translocation, suppressed IκBα phosphorylation and degradation, and inhibited phosphorylation of ERK, JNK, and p38 MAPKs.
Animal Model: Male ICR mice, weighing 25-35 g and 8 weeks of age, were used to establish scopolamine-induced amnesic models[5]
Dosage: 8.5 mg/kg (25 μmol/kg)
Administration: i.p. 1 hour before Scopolamine (0.5 mg/kg, i.p.)
Result: Improved scopolamine-induced cognitive deficits in male ICR mice.
Increased the time spent in the target quadrant (Q1) in the Morris water maze test.
Molecular Weight

339.39

Formula

C20H21NO4
CAS No.
Appearance

Solid

Color

Off-white to light yellow

SMILES

CN1CCC(C2=C3C4=CC=C(OC)C(OC)=C4C[C@@]12[H])=CC5=C3OCO5
Structure Classification
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility
In Vitro: 

DMSO : 100 mg/mL (294.65 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 2.9465 mL 14.7323 mL 29.4646 mL
5 mM 0.5893 mL 2.9465 mL 5.8929 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

    Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

    Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
  • Protocol 2

    Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

    Solubility: ≥ 2.5 mg/mL (7.37 mM); Clear solution

    This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

    Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

    Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
%
DMSO +
% 
+
%
Tween-80 +
%
Saline
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Calculation results:
Working solution concentration: mg/mL
Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
 If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Purity & Documentation

Purity: 99.83%

SDS (393 KB)

COA (256 KB) HNMR (282 KB) LCMS (98 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
DMSO 1 mM 2.9465 mL 14.7323 mL 29.4646 mL 73.6616 mL
5 mM 0.5893 mL 2.9465 mL 5.8929 mL 14.7323 mL
10 mM 0.2946 mL 1.4732 mL 2.9465 mL 7.3662 mL
15 mM 0.1964 mL 0.9822 mL 1.9643 mL 4.9108 mL
20 mM 0.1473 mL 0.7366 mL 1.4732 mL 3.6831 mL
25 mM 0.1179 mL 0.5893 mL 1.1786 mL 2.9465 mL
30 mM 0.0982 mL 0.4911 mL 0.9822 mL 2.4554 mL
40 mM 0.0737 mL 0.3683 mL 0.7366 mL 1.8415 mL
50 mM 0.0589 mL 0.2946 mL 0.5893 mL 1.4732 mL
60 mM 0.0491 mL 0.2455 mL 0.4911 mL 1.2277 mL
80 mM 0.0368 mL 0.1842 mL 0.3683 mL 0.9208 mL
100 mM 0.0295 mL 0.1473 mL 0.2946 mL 0.7366 mL
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Crebanine Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Crebanine25127-29-1AktApoptosisNF-κBReactive Oxygen Species (ROS)p38 MAPKERKInterleukin RelatedTNF ReceptorNO SynthasenAChRBacterialPKBProtein kinase BNuclear factor-κBNuclear factor-kappaBExtracellular signal regulated kinasesILTumor Necrosis Factor ReceptorTNFRNitric oxide synthasesNOSNicotinic acetylcholine receptorshepatocellular carcinoma (HCC)cerebral ischemiaAKT/FoxO3aMAPKAlzheimer's diseasebacteriaInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Crebanine
Cat. No.:
HY-N2255
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (393 KB) Français - FR (393 KB) Deutsch - DE (393 KB) Norwegian - NO (393 KB) Español - ES (393 KB) Swedish - SV (393 KB) Italian - IT (393 KB) Portuguese - PT (393 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.